Loading...

Robert Grant, MD, MPH

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Ave, HSE
San Francisco CA 94143
Phone--
ORCID ORCID Icon0000-0002-0851-7085 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoFellowship1996Pulmonary Medicine
    University of California, San Francisco Residency 1991School of Medicine
    University of California, San FranciscoM.D.1988 Medicine
    University of California, Berkeley M.P.H1986 Epidemiology
    University of California, BerkeleyM.H.S.1986Health and Medical Sciences
    Stanford UniversityB.S., A.B1983Biology, Latin American Studies
    California Institute of Integral Studies, San FranciscoCertificate2016Psychedelic Treatment and Research
    Collapse Awards and Honors
    IAPAC2017150 Pioneers and Leaders in the AIDS Response
    2012Association of American Physicians
    Time Magazine2012100 most influencial persons
    San Francisco AIDS Foundation2011Leadership Award
    Time Magazine2011People Who Mattered
    2003American Society Clinical Investigation
    UCSF1988Alpha Omega Alpha
    Stanford1983Phi Beta Kappa

    Collapse Overview 
    Collapse Overview
    Dr. Grant believes that clinical and public health practice inspires the best research. His goal is to find ways for people to breath more easily, and to end HIV transmission and disease. His work with HIV started in 1983 with the epidemic when he was a graduate student in epidemiology at UC Berkeley. With the completion of his work pioneering HIV pre-exposure prophylaxis (or PrEP) in 2014, he pivoted to focus on the underpinnings of the epidemic, including stigma, trauma, injustice, addiction, and depression. His current clinical practice is on pulmonary medicine, and how breathing intersects with emotional well being. The next phase of his research focuses on novel transformative interventions for depression and anxiety, including ketamine and MDMA assisted psychotherapies.

    Dr. Grant has had a clinical practice in pulmonary and critical care medicine from 1994 to the present, including at Zuckerberg San Francisco General Hospital, San Francisco Veterans Administration Medical Center, and UCSF Health. He started the Sexual Health Improvement Project at UCSF in 2014; this was the first clinical service at UCSF to offer HIV preexposure prophylaxis. He served as the Chief Medical Officer of the San Francisco AIDS Foundation from 2014 to 2018, where he oversaw the initiation of the largest PrEP service in San Francisco, HIV treatment initiation in a sexual health clinic, and HCV treatment linked with a needle exchange site. The SFAF PrEP service is innovative in being rooted in a community based organization, led by nurses, pioneering same day PrEP initiation (and later, same-day HIV treatment initiation), and offering education for non-daily or 2-1-1 PrEP dosing.

    Dr. Grant has served as an advisor for laboratory medicine, antiretroviral therapy, and pre-exposure prophylaxis to the CDC, the FDA, and the WHO. He helped develop the WHO recommendation for PrEP (AIDS 2016) and he drafted the WHO PrEP Implementation Tool Kit in consultation with hundreds of experts and stakeholders around the world (https://www.who.int/hiv/pub/prep/prep-implementation-tool/en/). He co-founded a ketamine assisted psychotherapy practice called "Healing Realms" in 2017, and now serves on the board of directors of the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP). He is a mentor in the California Institute of Integral Studies Certificate Program in Psychedelic Treatment and Research (CIIS CPTR).

    Key findings from Dr. Grant's research include the following:

    1. Conceptualization and estimation of transmissibility: Dr. Grant developed the concept of transmissibility (now denoted with "beta") and developed a method for estimating transmission of HIV per sexual contact and per sexual partner using epidemiological data (JID 1987). This parameter formed the basis of a generation of mathematical models of infectious epidemics.

    2. Diagnostic innovations that guide therapy: Dr. Grant was the first to demonstrate that oral fluid could be used for HIV diagnostic antibody testing (CDLI 1996). He later conducted research that led to the first sequence based assay for drug resistance (or any other condition) to be approved by the FDA (J Clin Micro 2003).

    3. High viral load in nonpathogenic SIV infections: Dr. Grant's laboratory discovered a null allele of CCR5 in the natural host of simian immunodeficiency virus. The host genotype was associated with viral load in nonpathogenic infection (Current Biology 1998).

    4. Drug resistant HIV has diminished clinical consequences: First case report of transmission of protease inhibitor resistant HIV-1 (NEJM 1998). Finding that primary drug resistance to certain classes of antiretroviral therapy is increasing overtime, and is associated with delayed virological responses to therapy (JAMA 2002). Finding that drug resistant viremia is associated with preserved CD4+ T cell count responses to therapy, suggesting a trade-off for the virus between resistance and virulence (AIDS 1999). Persistent partial CD4+ T cell count responses proved to require continued exposure to therapy that retains partial antiviral activity and maintains selection for viruses with diminished replication capacity (NEJM 2001).

    5. Pre-exposure Prophylaxis is safe, effective, and feasible: Dr. Grant's iPrEx trial found that daily oral emtricitabine/tenofovir disoproxil fumarate decreases HIV acquisition among men who have sex with men and transgender women (NEJM 2010). He also conducted the first open label demonstration project of preexposure prophylaxis, showing that adherence is higher when information about safety and efficacy is provided (Lancet ID 2014). He published the first and still largest series of PrEP use among transgender women (Deutsch 2015). He and his colleagues Identified a correlate of protection and a candidate surrogate marker for efficacy of pre-exposure prophylaxis (Anderson 2012).

    Collapse Research 
    Collapse Research Activities and Funding
    Ketamine therapy for Palliative Care
    Osher Center Jul 1, 2020 - Jun 30, 2021
    Role: Co-investigator, mentor
    Chemoprophylaxis and HIV Host Interactions
    NIH/NIAID R01AI118575Feb 15, 2018 - Apr 30, 2020
    Role: Principal Investigator
    The Biology of HIV Transmission
    NIH/NIAID P01AI071713Sep 1, 2007 - Aug 31, 2013
    Role: Co-Investigator
    Chemoprophylaxis for HIV Prevention in Men
    NIH/NIAID U01AI064002Aug 15, 2005 - Jun 30, 2011
    Role: Principal Investigator
    Chemoprophylaxis and HIV-Host Interactions
    NIH/NIAID R01AI062333Sep 1, 2004 - Mar 31, 2013
    Role: Principal Investigator
    Mechanisms Blocking HIV-1 Superinfection
    NIH/NIAID R01AI056988Dec 1, 2003 - Nov 30, 2007
    Role: Principal Investigator
    GENDER EFFECTS ON HIV BIOLOGY
    NIH/NICHD P01HD040543Apr 23, 2001 - Mar 31, 2008
    Role: Co-Investigator
    Support of Yerkes National Primate Research Center
    NIH/NCRR P51RR000165Jun 1, 1976 - Sep 30, 2010
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Sep 29, 2006
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the iBrEATHe Study. Clin Infect Dis. 2020 Aug 08. Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV, O'Neal J, Yager J, Bhasin S, Sevelius J, Deutsch MB. PMID: 32766890.
      View in: PubMed   Mentions:    Fields:    
    2. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020 07 25; 396(10246):239-254. Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. PMID: 32711800.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    3. Use of Drug-Level Testing and Single-Genome Sequencing to Unravel a Case of HIV Seroconversion on PrEP. Clin Infect Dis. 2020 Jul 20. Spinelli MA, Lowery B, Shuford JA, Spindler J, Kearney MF, McFarlane JR, McDonald C, Okochi H, Phung N, Kuncze K, Jee K, Johannessen D, Anderson PL, Smith DK, Defechereux P, Grant RM, Gandhi M. PMID: 32686825.
      View in: PubMed   Mentions:    Fields:    
    4. Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study. Clin Infect Dis. 2020 Jul 11; 71(2):249-255. Dimitrov D, Moore JR, Wood D, Mitchell KM, Li M, Hughes JP, Donnell DJ, Mannheimer S, Holtz TH, Grant RM, Boily MC. PMID: 31437276.
      View in: PubMed   Mentions:    Fields:    
    5. The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT. AIDS Behav. 2020 Jul; 24(7):2178-2187. Velloza J, Heffron R, Amico KR, Rowhani-Rahbar A, Hughes JP, Li M, Dye BJ, Celum C, Bekker LG, Grant RM. PMID: 31955360.
      View in: PubMed   Mentions:    Fields:    
    6. Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations. J Acquir Immune Defic Syndr. 2020 Jun 01; 84(2):149-152. Spinelli MA, Rodrigues WC, Wang G, Vincent M, Glidden DV, Okochi H, Stalter R, Defechereux P, Deutsch M, Grant RM, Ngure K, Mugo NR, Baeten JM, Gandhi M. PMID: 32167963.
      View in: PubMed   Mentions:
    7. HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health. AIDS. 2020 04 01; 34(5):699-706. Ascher SB, Scherzer R, Estrella MM, Shigenaga J, Spaulding KA, Glidden DV, Mehrotra ML, Defechereux P, Gandhi M, Grant RM, Shlipak MG, Jotwani V. PMID: 31794523.
      View in: PubMed   Mentions: 1     Fields:    
    8. Community pharmacy delivered PrEP to STOP HIV transmission: An opportunity NOT to miss! J Am Pharm Assoc (2003). 2020 Jul - Aug; 60(4):e18-e24. Lopez MI, Grant RM, Dong BJ. PMID: 32165026.
      View in: PubMed   Mentions:    Fields:    
    9. "A Good Habit": Telehealth PrEP Users Find Benefit in Quarterly Monitoring Requirements. J Int Assoc Provid AIDS Care. 2020 Jan-Dec; 19:2325958220919269. Koester KA, Hughes SD, Grant RM. PMID: 32323593.
      View in: PubMed   Mentions:    Fields:    
    10. Response to: Acceptability and Feasibility of a Pharmacist-Led HIV Pre-exposure Prophylaxis Program in the Midwestern United States. Open Forum Infect Dis. 2019 Dec; 6(12):ofz497. Dong BJ, Lopez MI, Grant RM. PMID: 31824977.
      View in: PubMed   Mentions:
    11. HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013. J Acquir Immune Defic Syndr. 2019 10 01; 82(2):e18-e26. Holtz TH, Chitwarakorn A, Hughes JP, Curlin ME, Varangrat A, Li M, Amico KR, Mock PA, Grant RM. PMID: 31490342.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    12. Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. J Acquir Immune Defic Syndr. 2019 10 01; 82(2):149-158. Velloza J, Bacchetti P, Hendrix CW, Murnane P, Hughes JP, Li M, Curlin ME, Holtz TH, Mannheimer S, Marzinke MA, Amico KR, Liu A, Piwowar-Manning E, Eshleman SH, Dye BJ, Gandhi M, Grant RM. PMID: 31335588.
      View in: PubMed   Mentions:
    13. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study. J Acquir Immune Defic Syndr. 2019 09 01; 82(1):34-40. Ojeda VD, Amico KR, Hughes JP, Wilson E, Li M, Holtz TH, Chitwarakorn A, Grant RM, Dye BJ, Bekker LG, Mannheimer S, Marzinke M, Hendrix CW. PMID: 31169769.
      View in: PubMed   Mentions:
    14. Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California. J Acquir Immune Defic Syndr. 2019 08 01; 81(4):406-413. Myers JJ, Kang Dufour MS, Koester KA, Udoh I, Frazier R, Packard R, Kennedy K, Erguera X, Horowitz J, Grant R, Burack JH. PMID: 30973542.
      View in: PubMed   Mentions:
    15. Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial. J Acquir Immune Defic Syndr. 2019 07 01; 81(3):e94-e98. Mehrotra ML, Westreich D, McMahan VM, Glymour MM, Geng E, Grant RM, Glidden DV. PMID: 31192894.
      View in: PubMed   Mentions:
    16. Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. AIDS Res Hum Retroviruses. 2019 09; 35(9):788-793. Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM. PMID: 31119944.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    17. Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067/ADAPT Study. AIDS Care. 2020 02; 32(2):249-254. Chemnasiri T, Varangrat A, Amico KR, Chitwarakorn A, Dye BJ, Grant RM, Holtz TH. PMID: 31159584.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    18. Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. J Acquir Immune Defic Syndr. 2019 05 01; 81(1):78-82. Hojilla JC, Satre DD, Glidden DV, McMahan VM, Gandhi M, Defechereux P, Guanira JV, Mehrotra M, Grant RM, Carrico AW. PMID: 30730359.
      View in: PubMed   Mentions:
    19. Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. J Acquir Immune Defic Syndr. 2019 04 15; 80(5):551-558. Mannheimer S, Hirsch-Moverman Y, Franks J, Loquere A, Hughes JP, Li M, Amico KR, Grant RM. PMID: 30865051.
      View in: PubMed   Mentions:
    20. Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. AIDS. 2019 04 01; 33(5):867-872. Spinelli MA, Glidden DV, Rodrigues WC, Wang G, Vincent M, Okochi H, Kuncze K, Mehrotra M, Defechereux P, Buchbinder SP, Grant RM, Gandhi M. PMID: 30649051.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    21. Increased uptake of early initiation of antiretroviral therapy and baseline drug resistance testing in San Francisco between 2001 and 2015. PLoS One. 2019; 14(3):e0213167. Truong HM, Pipkin S, Grant RM, Liegler T, O'Keefe KJ, Scheer S. PMID: 30870438.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018 Nov 29. Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, Okochi H, Anderson PL, Kearney MF, Coffey S, Scott H, Grant RM, Havlir D, Gandhi M. PMID: 30503324.
      View in: PubMed   Mentions: 11     Fields:    
    23. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV Clin Trials. 2018 08; 19(4):129-138. Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, Stancil BS, Ford SL, Patel P, Rinehart AR, Spreen WR, Margolis DA. PMID: 30445896.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    24. The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. AIDS Behav. 2018 Nov; 22(11):3673-3680. Mehrotra ML, Rivet Amico K, McMahan V, Glidden DV, Defechereux P, Guanira JV, Grant RM. PMID: 29754268.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    25. Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis. Open Forum Infect Dis. 2018 Sep; 5(9):ofy197. Stekler JD, Violette LR, Niemann L, McMahan VM, Katz DA, Baeten JM, Grant RM, Delaney KP. PMID: 30276221.
      View in: PubMed   Mentions:
    26. "Losing the Phobia:" Understanding How HIV Pre-exposure Prophylaxis Facilitates Bridging the Serodivide Among Men Who Have Sex With Men. Front Public Health. 2018; 6:250. Koester KA, Erguera XA, Kang Dufour MS, Udoh I, Burack JH, Grant RM, Myers JJ. PMID: 30238001.
      View in: PubMed   Mentions:
    27. Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. Clin Infect Dis. 2018 08 31; 67(6):962-964. Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, Ananworanich J, Robb ML, Phanuphak N. PMID: 29961859.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsPHPublic Health
    28. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis. 2018 07 18; 67(3):411-419. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. PMID: 29415175.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    29. Characterization of HIV Recent Infection Among High-Risk Men at Public STI Clinics in Mumbai. AIDS Behav. 2018 Jul; 22(Suppl 1):70-75. Truong HM, Fatch R, Grant RM, Mathur M, Kumta S, Jerajani H, Kellogg TA, Lindan CP. PMID: 29453551.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):169-174. Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG. PMID: 29767638.
      View in: PubMed   Mentions:
    31. Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study. Front Public Health. 2018; 6:151. Ryan KE, Mak A, Stoove M, Price B, Fairley CK, Ruth S, Lal L, Asselin J, El-Hayek C, Nguyen L, Batrouney C, Wilson D, Lockwood J, Murphy D, Cornelisse VJ, Roth N, Willcox J, Chang CC, Armishaw J, Tee BK, Penn M, Forgan-Smith G, Williams C, Montgomery J, Byron K, Coelho A, Allen B, Wiggins J, Kelsall J, Vujovic O, West M, Pierce AB, Gallant D, Bell C, de Wit JBF, Hoy JF, Wesselingh SL, Grant RM, Wright EJ. PMID: 29896468.
      View in: PubMed   Mentions:
    32. Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Clin Infect Dis. 2018 05 17; 66(11):1712-1721. Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, Stirratt M, Rooney JF, Eshleman SH, McNicholl JM, van Griensven F, Holtz TH. PMID: 29420695.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    33. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol. 2018 07; 32(7):779-792. Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E. PMID: 29708042.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    34. Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. PLoS One. 2018; 13(4):e0195764. Figueroa DB, Tillotson J, Li M, Piwowar-Manning E, Hendrix CW, Holtz TH, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant RM, Bumpus NN. PMID: 29641561.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    35. Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study. AIDS Behav. 2018 04; 22(4):1139-1149. Franks J, Hirsch-Moverman Y, Loquere AS, Amico KR, Grant RM, Dye BJ, Rivera Y, Gamboa R, Mannheimer SB. PMID: 29143163.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansPHPublic Health
    36. In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? AIDS. 2018 03 27; 32(6):809-818. Mitchell KM, Dimitrov D, Hughes JP, Xia F, Donnell D, Amico KR, Bokoch K, Chitwarakorn A, Bekker LG, Holtz TH, Mannheimer S, Grant RM, Boily MC. PMID: 29424774.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    37. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis. J Int AIDS Soc. 2018 03; 21(3):e25103. Hojilla JC, Vlahov D, Glidden DV, Amico KR, Mehrotra M, Hance R, Grant RM, Carrico AW. PMID: 29577616.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    38. A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. AIDS Patient Care STDS. 2018 03; 32(3):104-111. Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR, Kouyate A, Gilmore HJ, Buchbinder SP, Lester RT, Grant RM, Liu AY. PMID: 29565183.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    39. Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. J Clin Virol. 2018 Feb - Mar; 99-100:67-70. Eshleman SH, Piwowar-Manning E, Sivay MV, Debevec B, Veater S, McKinstry L, Bekker LG, Mannheimer S, Grant RM, Chesney MA, Coates TJ, Koblin BA, Fogel JM. PMID: 29346085.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    40. Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. PLoS One. 2018; 13(1):e0190118. Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, Anderson PL, Grant R, Greenblatt RM, Buchbinder S, Gandhi M, Liu AY. PMID: 29315307.
      View in: PubMed   Mentions: 8     Fields:    Translation:PHPublic Health
    41. Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):e104-e106. Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, Mohri H. PMID: 29076941.
      View in: PubMed   Mentions:
    42. HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis. AIDS Care. 2018 04; 30(4):466-472. Hojilla JC, Mehrotra M, Truong HM, Glidden DV, Amico KR, McMahan V, Vlahov D, Chariyalertsak S, Guanira JV, Grant RM. PMID: 29082776.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    43. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2018 02; 5(2):e68-e78. Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM. PMID: 28986029.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    44. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. J Acquir Immune Defic Syndr. 2017 10 01; 76(2):177-182. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. PMID: 28639995.
      View in: PubMed   Mentions:
    45. Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. AIDS. 2017 07 31; 31(12):1709-1714. Lal L, Audsley J, Murphy DA, Fairley CK, Stoove M, Roth N, Moore R, Tee BK, Puratmaja N, Anderson PL, Leslie D, Grant RM, De Wit J, Wright E. PMID: 28700394.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansPHPublic Health
    46. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr. 2017 07 01; 75(3):271-279. Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH. PMID: 28328548.
      View in: PubMed   Mentions:
    47. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017 08; 4(8):e331-e340. Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR, Smith KY, Spreen WR. PMID: 28546090.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    48. Is pericoital or peri-insemination preexposure prophylaxis effective human immunodeficiency prevention for vaginal exposures? Am J Obstet Gynecol. 2017 08; 217(2):230-231. Seidman DL, Weber S, Grant RM. PMID: 28479285.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    49. International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. Sex Transm Dis. 2017 05; 44(5):306-309. Truong HM, Mehrotra M, Montoya O, Lama JR, Guanira JV, Casapía M, Veloso VG, Buchbinder SP, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM. PMID: 28407648.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. AIDS Behav. 2017 May; 21(5):1325-1335. Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, Rodolph M, Hodges-Mameletzis I, Kennedy CE. PMID: 27900502.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansPHPublic Health
    51. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. AIDS Behav. 2017 May; 21(5):1361-1375. Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, Dye BJ, Elharrar V, Grant RM. PMID: 27317411.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic Health
    52. Risk, safety and sex among male PrEP users: time for a new understanding. Cult Health Sex. 2017 Dec; 19(12):1301-1313. Koester K, Amico RK, Gilmore H, Liu A, McMahan V, Mayer K, Hosek S, Grant R. PMID: 28415911.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    53. Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to Treponema pallidum? Sex Transm Infect. 2017 08; 93(5):313. Glidden DV, Mayer K, Grant RM. PMID: 28408646.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    54. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Res Hum Retroviruses. 2017 08; 33(8):778-783. Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M. PMID: 28253024.
      View in: PubMed   Mentions: 25     Fields:    
    55. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016; 19(7(Suppl 6)):21105. Sevelius JM, Deutsch MB, Grant R. PMID: 27760683.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    56. Pharmacology supports on-demand PrEP. Lancet HIV. 2016 09; 3(9):e405-e406. Glidden DV, Anderson PL, Grant RM. PMID: 27562738.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    57. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV. 2016 11; 3(11):e521-e528. Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM. PMID: 27658870.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    58. Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr. 2016 08 15; 72 Suppl 3:S226-9. Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB. PMID: 27429187.
      View in: PubMed   Mentions:
    59. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016 07 31; 30(12):1973-83. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM. PMID: 27149090.
      View in: PubMed   Mentions: 149     Fields:    Translation:HumansPHPublic Health
    60. HIV Serodisclosure and Sexual Behavior During International Travel. Sex Transm Dis. 2016 07; 43(7):459-64. Truong HM, Chen YH, Grasso M, Robertson T, Tao L, Fatch R, Curotto A, McFarland W, Grant RM, Reznick O, Raymond HF, Steward WT. PMID: 27322049.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    61. The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. AIDS Behav. 2016 07; 20(7):1527-34. Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, Mayer KH, Veloso VG, Bekker LG, Avelino-Silva VI, Schechter M, Grant RM. PMID: 27125241.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    62. Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). AIDS Behav. 2016 07; 20(7):1478-88. Defechereux PA, Mehrotra M, Liu AY, McMahan VM, Glidden DV, Mayer KH, Vargas L, Amico KR, Chodacki P, Fernandez T, Avelino-Silva VI, Burns D, Grant RM. PMID: 26078115.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    63. Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial. J Acquir Immune Defic Syndr. 2016 Jun 01; 72(2):184-8. Kuebler PJ, Shaw BI, Leadabrand KS, Mehrotra ML, Grant RM, Kallás EG, Nixon DF. PMID: 26674373.
      View in: PubMed   Mentions:
    64. PrEP adherence among trans women in Brazil-access needed for this key population - Authors' reply. Lancet HIV. 2016 05; 3(5):e200-1. Sevelius J, Deutsch MB, Glidden DV, Grant RM. PMID: 27126486.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    65. PO-60 - Renal tumors with extensive vascular disease: management challenges in a pediatric series from the Hospital for Sick Children. Thromb Res. 2016 Apr; 140 Suppl 1:S198-9. Zamperlini-Netto G, Zanette A, Wehbi E, Williams S, Grant RM, Brandao LR. PMID: 27161746.
      View in: PubMed   Mentions: 1     Fields:    
    66. HIV moments and pre-exposure prophylaxis. Lancet. 2016 Apr 09; 387(10027):1507-1508. Grant RM, Glidden DV. PMID: 27115970.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    67. Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):e115-8. Yacoub R, Nadkarni GN, Weikum D, Konstantinidis I, Boueilh A, Grant RM, Mugwanya KK, Baeten JM, Wyatt CM. PMID: 26627105.
      View in: PubMed   Mentions:
    68. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. J Acquir Immune Defic Syndr. 2016 03 01; 71(3):281-6. Solomon MM, Schechter M, Liu AY, McMahan VM, Guanira JV, Hance RJ, Chariyalertsak S, Mayer KH, Grant RM. PMID: 26413853.
      View in: PubMed   Mentions:
    69. Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis. 2016 May 01; 62(9):1172-7. Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM. PMID: 26797207.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    70. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med. 2016 Jan; 176(1):75-84. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA. PMID: 26571482.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    71. What people want from sex and preexposure prophylaxis. Curr Opin HIV AIDS. 2016 Jan; 11(1):3-9. Grant RM, Koester KA. PMID: 26569183.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    72. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015 Dec; 2(12):e512-9. Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM. PMID: 26614965.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansPHPublic Health
    73. Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis. Clin Infect Dis. 2015 Nov 15; 61(10):1604-5. Koester KA, Grant RM. PMID: 26334051.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    74. Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation. J Infect Dis. 2016 Feb 15; 213(4):569-73. Kuebler PJ, Mehrotra ML, Shaw BI, Leadabrand KS, Milush JM, York VA, Defechereux P, Grant RM, Kallás EG, Nixon DF. PMID: 26310308.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    75. Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. Open Forum Infect Dis. 2015 Dec; 2(4):ofv126. Grant RM, Smith DK. PMID: 26512356.
      View in: PubMed   Mentions:
    76. Brief Report: Recent Infection, Sexually Transmitted Infections, and Transmission Clusters Frequently Observed Among Persons Newly Diagnosed With HIV in San Francisco. J Acquir Immune Defic Syndr. 2015 Aug 15; 69(5):606-9. Truong HM, Pipkin S, O'Keefe KJ, Louie B, Liegler T, McFarland W, Grant RM, Bernstein K, Scheer S. PMID: 25967271.
      View in: PubMed   Mentions:
    77. Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8379-84. Kuebler PJ, Mehrotra ML, McConnell JJ, Holditch SJ, Shaw BI, Tarosso LF, Leadabrand KS, Milush JM, York VA, Raposo RA, Cheng RG, Eriksson EM, McMahan V, Glidden DV, Shiboski S, Grant RM, Nixon DF, Kallás EG. PMID: 26100867.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    78. Ending sexual HIV transmission: lessons learned from perinatal HIV. J Assoc Nurses AIDS Care. 2015 Sep-Oct; 26(5):520-5. Weber S, Grant RM. PMID: 26096627.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    79. The FACTS about women and pre-exposure prophylaxis. Lancet HIV. 2015 Jun; 2(6):e228. Seidman D, Weber S, Aaron E, Cohan D, Grant R. PMID: 26423194.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    80. Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study. AIDS Care. 2015; 27(10):1199-204. Koester KA, Liu A, Eden C, Amico KR, McMahan V, Goicochea P, Hosek S, Mayer KH, Grant RM. PMID: 26001026.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    81. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2015 Aug 15; 61(4):572-80. Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM. PMID: 25908682.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    82. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. J Infect Dis. 2015 Nov 01; 212(9):1402-6. Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, Guanira JV, Grinsztejn B, Chariyalertsak S, Bekker LG, Grant RM. PMID: 25895984.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansPHPublic Health
    83. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015 Jan 28; 29(3):331-7. Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV. PMID: 25503265.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsPHPublic Health
    84. Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis. J Infect Dis. 2015 Apr 15; 211(8):1202-4. Grant RM, Liegler T. PMID: 25587019.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    85. Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24Gag. Bio Protoc. 2014 Dec 20; 4(24). Gesner M, Maiti M, Grant R, Cavrois M. PMID: 27525295.
      View in: PubMed   Mentions:
    86. Transactional sex and prevalence of STIs: a cross-sectional study of MSM and transwomen screened for an HIV prevention trial. Int J STD AIDS. 2015 Oct; 26(12):879-86. Solomon MM, Nureña CR, Tanur JM, Montoya O, Grant RM, McConnell JJ. PMID: 25520017.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    87. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014 Dec 15; 67(5):528-37. Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R. PMID: 25230290.
      View in: PubMed   Mentions:
    88. Streamlining HIV testing for HIV preexposure prophylaxis. J Clin Microbiol. 2015 Jan; 53(1):179-83. Guanira JV, Leigler T, Kallas E, Schechter M, Sharma U, Glidden D, Grant RM. PMID: 25378570.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsPHPublic Health
    89. Gay and bisexual men engage in fewer risky sexual behaviors while traveling internationally: a cross-sectional study in San Francisco. Sex Transm Infect. 2015 May; 91(3):220-5. Truong HM, Fatch R, Grasso M, Robertson T, Tao L, Chen YH, Curotto A, McFarland W, Grant RM, Reznick O, Raymond HF, Steward WT. PMID: 25355773.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    90. Reply to Boyd et al. Clin Infect Dis. 2015 Jan 15; 60(2):327. Solomon MM, Mayer KH, Glidden DV, Guanira JV, Grant RM. PMID: 25323702.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    91. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. . 2014 Aug 15; 66(5):530-7. Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, Anderson PL, Glidden D, Guanira J, Grant R. PMID: 24853306.
      View in: PubMed   Mentions:
    92. Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition. Clin Pharmacol Ther. 2014 Aug; 96(2):153-5. Miller V, Grant RM. PMID: 25056397.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    93. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014 Sep; 14(9):820-9. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, Hosek S, Mosquera C, Casapia M, Montoya O, Buchbinder S, Veloso VG, Mayer K, Chariyalertsak S, Bekker LG, Kallas EG, Schechter M, Guanira J, Bushman L, Burns DN, Rooney JF, Glidden DV. PMID: 25065857.
      View in: PubMed   Mentions: 352     Fields:    Translation:Humans
    94. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014 Jul 23-30; 312(4):390-409. Marrazzo JM, del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, Montaner JS, Wheeler DP, Grant RM, Grinsztejn B, Kumarasamy N, Shoptaw S, Walensky RP, Dabis F, Sugarman J, Benson CA. PMID: 25038358.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    95. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clin Infect Dis. 2014 Oct; 59(7):1020-6. Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, Chariyalertsak S, Fernandez T, Grant RM. PMID: 24928295.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansPHPublic Health
    96. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014 Oct 15; 210(8):1217-27. Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM. PMID: 24740633.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    97. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014 Mar 27; 28(6):851-9. Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, Guanira JV, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Burns DN, Grant RM. PMID: 24499951.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    98. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One. 2014; 9(3):e91513. Marcus JL, Glidden DV, McMahan V, Lama JR, Mayer KH, Liu AY, Montoya-Herrera O, Casapia M, Hoagland B, Grant RM. PMID: 24637511.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    99. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014 Jun; 14(6):468-75. Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, Goicochea P, Grant RM. PMID: 24613084.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    100. Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions. HIV Med. 2014 Aug; 15(7):385-95. Marcus JL, Buisker T, Horvath T, Amico KR, Fuchs JD, Buchbinder SP, Grant RM, Liu AY. PMID: 24580813.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    101. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014; 9(1):e83736. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M. PMID: 24421901.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    102. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013; 8(12):e81997. Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM. PMID: 24367497.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    103. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. . 2013 Sep 01; 64(1):79-86. Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, Collins BM, Pathak SR, O'hara B, Ackers ML, Rose CE, Grant RM, Paxton LA, Buchbinder SP. PMID: 23466649.
      View in: PubMed   Mentions:
    104. Changes in seroadaptive practices from before to after diagnosis of recent HIV infection among men who have sex with men. PLoS One. 2013; 8(2):e55397. Vallabhaneni S, McConnell JJ, Loeb L, Hartogensis W, Hecht FM, Grant RM, Pilcher CD. PMID: 23405145.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    105. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med. 2012; 9(10):e1001323. Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, Hallett TB. PMID: 23055836.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    106. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012 Sep 12; 4(151):151ra125. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM. PMID: 22972843.
      View in: PubMed   Mentions: 316     Fields:    Translation:Humans
    107. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012 Jul; 16(5):1243-59. R Amico K, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant RM, Liu A. PMID: 22460228.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    108. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One. 2011; 6(10):e25281. Truong HM, Kellogg TA, McFarland W, Louie B, Klausner JD, Philip SS, Grant RM. PMID: 22046237.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCellsPHPublic Health
    109. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011 Apr 15; 203(8):1174-81. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM. PMID: 21451005.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    110. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One. 2010 Dec 10; 5(12):e15510. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant RM, Deeks SG, Hecht FM. PMID: 21170322.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    111. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011 Feb; 66(2):240-50. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. PMID: 21118913.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    112. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30; 363(27):2587-99. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. PMID: 21091279.
      View in: PubMed   Mentions: 1646     Fields:    Translation:HumansCells
    113. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S96-101. Grant RM. PMID: 20397962.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansPHPublic Health
    114. HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS. 2010 Apr 24; 24(7):941-5. Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J, Deeks SG. PMID: 20168202.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsPHPublic Health
    115. Sexual seroadaptation: lessons for prevention and sex research from a cohort of HIV-positive men who have sex with men. PLoS One. 2010 Jan 21; 5(1):e8831. McConnell JJ, Bragg L, Shiboski S, Grant RM. PMID: 20098616.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    116. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol. 2009 Jul; 15(4):324-33. Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, Lampiris H, Neuhaus J, Grant RM, Chao LL, Truran D, Weiner MW. PMID: 19499454.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    117. Frequent international travel by men who have sex with men recently diagnosed with HIV-1: potential for transmission of primary HIV-1 drug resistance. J Travel Med. 2008 Nov-Dec; 15(6):454-6. Truong HM, Kellogg T, Schwarcz S, Delgado V, Grant RM, Louie B, Ngo H, McFarland W. PMID: 19090802.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    118. Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS Pathog. 2008 Oct; 4(10):e1000185. Willberg CB, McConnell JJ, Eriksson EM, Bragg LA, York VA, Liegler TJ, Hecht FM, Grant RM, Nixon DF. PMID: 18949024.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    119. Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level. Clin Vaccine Immunol. 2008 Nov; 15(11):1745-8. Erickson AL, Willberg CB, McMahan V, Liu A, Buchbinder SP, Grohskopf LA, Grant RM, Nixon DF. PMID: 18815234.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    120. Whither or wither microbicides? Science. 2008 Jul 25; 321(5888):532-4. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA. PMID: 18653884.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansAnimalsCells
    121. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog. 2007 Oct 26; 3(10):1477-85. Bourara K, Liegler TJ, Grant RM. PMID: 17967058.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    122. Research in situ. Nat Methods. 2007 Nov; 4(11):887-90. Grant RM. PMID: 17952085.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    123. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. AIDS Res Hum Retroviruses. 2007 Jan; 23(1):77-85. Abrams DI, Shade SB, Couey P, McCune JM, Lo J, Bacchetti P, Chang B, Epling L, Liegler T, Grant RM. PMID: 17263636.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    124. Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex Transm Infect. 2006 Dec; 82(6):461-6. Truong HM, Truong HH, Kellogg T, Klausner JD, Katz MH, Dilley J, Knapper K, Chen S, Prabhu R, Grant RM, Louie B, McFarland W. PMID: 17151031.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    125. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem. 2007 Feb 09; 282(6):3539-46. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC. PMID: 17110377.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCells
    126. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS. 2006 Nov 14; 20(17):2193-7. Truong HM, Grant RM, McFarland W, Kellogg T, Kent C, Louie B, Wong E, Klausner JD. PMID: 17086059.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    127. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS. 2006 Oct 24; 20(16):2123-5. Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kelleher AD, Routy JP, Campbell TB, Rosenberg ES, Segal MR, Weidler J, Grant RM. PMID: 17053362.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    128. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol. 2006 Nov; 80(21):10407-18. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V. PMID: 16956949.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    129. Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis. 2006 Oct 01; 194(7):874-6. Grant RM, Wainberg MA. PMID: 16960773.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    130. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis. 2006 Oct 01; 43(7):904-10. Levy V, Grant RM. PMID: 16941375.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    131. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA. 2006 Aug 16; 296(7):863-5. Liu AY, Grant RM, Buchbinder SP. PMID: 16905792.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    132. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. . 2006 Aug 01; 42(4):501-5. Lama JR, Sanchez J, Suarez L, Caballero P, Laguna A, Sanchez JL, Whittington WL, Celum C, Grant RM. PMID: 16773026.
      View in: PubMed   Mentions:
    133. HIV drug-resistant strains as epidemiologic sentinels. Emerg Infect Dis. 2006 Feb; 12(2):191-7. Sánchez MS, Grant RM, Porco TC, Getz WM. PMID: 16494741.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    134. Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. . 2006 Jan 01; 41(1):68-74. Gange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R. PMID: 16340476.
      View in: PubMed   Mentions:
    135. High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection. . 2005 Dec 01; 40(4):463-71. Chin-Hong PV, Deeks SG, Liegler T, Hagos E, Krone MR, Grant RM, Martin JN. PMID: 16280703.
      View in: PubMed   Mentions:
    136. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis. 2005 Nov 15; 41(10):1507-13. Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, Busch MP, Hecht FM, Shacklett BL, Kahn JO, Bamberger JD, Coates TJ, Chesney MA, Martin JN. PMID: 16231265.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    137. AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science. 2005 Sep 30; 309(5744):2170-1. Grant RM, Buchbinder S, Cates W, Clarke E, Coates T, Cohen MS, Delaney M, Flores G, Goicochea P, Gonsalves G, Harrington M, Lama JR, MacQueen KM, Moore JP, Peterson L, Sanchez J, Thompson M, Wainberg MA. PMID: 16195446.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    138. Resistance testing in drug-naive HIV-infected patients: is it time? Clin Infect Dis. 2005 Nov 01; 41(9):1324-5. Hecht FM, Grant RM. PMID: 16206109.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    139. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005 Nov 01; 192(9):1537-44. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN. PMID: 16206068.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCellsCTClinical Trials
    140. Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. AIDS. 2005 Sep 02; 19(13):1351-9. Neuenburg JK, Furlan S, Bacchetti P, Price RW, Grant RM. PMID: 16103765.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    141. Detection of acute HIV infections. N Engl J Med. 2005 Aug 11; 353(6):631-3; author reply 631-3. Klausner JD, Grant RM, Kent CK. PMID: 16093476.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsPHPublic Health
    142. T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection. . 2005 May 01; 39(1):16-22. Neuenburg JK, Cho TA, Nilsson A, Bredt BM, Hebert SJ, Grant RM, Price RW. PMID: 15851909.
      View in: PubMed   Mentions:
    143. The role of viral fitness in HIV pathogenesis. Curr HIV/AIDS Rep. 2005 Feb; 2(1):29-34. Barbour JD, Grant RM. PMID: 16091246.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    144. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med. 2004 Dec; 1(3):e64. Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ. PMID: 15630469.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    145. A decrease in drug resistance levels of the HIV epidemic can be bad news. Bull Math Biol. 2005 Jul; 67(4):761-82. Sánchez MS, Grant RM, Porco TC, Gross KL, Getz WM. PMID: 15893552.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    146. HIV-producing T cells in cerebrospinal fluid. . 2004 Oct 01; 37(2):1237-44. Neuenburg JK, Sinclair E, Nilsson A, Kreis C, Bacchetti P, Price RW, Grant RM. PMID: 15385730.
      View in: PubMed   Mentions:
    147. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS. 2004 Aug 20; 18(12):1683-9. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, Grant RM. PMID: 15280779.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    148. HIV-1 superinfection and viral diversity. AIDS. 2004 Jul 23; 18(11):1513-20. Gross KL, Porco TC, Grant RM. PMID: 15238769.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    149. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol. 2004 Jul; 78(14):7392-9. Reyes-Sandoval A, Fitzgerald JC, Grant R, Roy S, Xiang ZQ, Li Y, Gao GP, Wilson JM, Ertl HC. PMID: 15220412.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    150. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis. 2004 Jul 15; 190(2):251-6. Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO, Grant RM. PMID: 15216458.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    151. The Clinical Implications of Reduced Viral Fitness. Curr Infect Dis Rep. 2004 Apr; 6(2):151-158. Barbour JD, Grant RM. PMID: 15023278.
      View in: PubMed   Mentions:
    152. Relating HIV-1 sequence variation to replication capacity via trees and forests. Stat Appl Genet Mol Biol. 2004; 3:Article2; discussion article 7, article 9. Segal MR, Barbour JD, Grant RM. PMID: 16646798.
      View in: PubMed   Mentions: 18     Fields:    
    153. Virological evaluation of the 'Ottawa case' indicates no evidence for HIV-1 superinfection. AIDS. 2004 Jan 23; 18(2):331-4. Angel JB, Hu YW, Kravcik S, Tsui R, Lee KH, Barbour J, Balaskas E, Branson BM, Delwart EL, Grant RM. PMID: 15075555.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    154. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004 Jan 02; 18(1):81-8. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, Osmond DH. PMID: 15090833.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    155. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol. 2004 Jan; 78(1):94-103. Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, Edlin BR, Delwart EL. PMID: 14671091.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    156. Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS. 2003 Nov 07; 17(16):2337-43. Papasavvas E, Grant RM, Sun J, Mackiewicz A, Pistilli M, Gallo C, Kostman JR, Mounzer K, Shull J, Montaner LJ. PMID: 14571185.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    157. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003 Sep 05; 17(13):1925-32. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. PMID: 12960825.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    158. Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients. . 2003 Aug 15; 33(5):655-6. Murphy EL, Grant RM, Kropp J, Oliveira A, Lee TH, Busch MP. PMID: 12902815.
      View in: PubMed   Mentions:
    159. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol. 2003 Jun; 77(12):6743-52. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. PMID: 12767994.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    160. Drug resistance mutations in HIV-1. Top HIV Med. 2003 May-Jun; 11(3):92-6. D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. PMID: 12837968.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    161. Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. Transfusion. 2003 Apr; 43(4):451-8. Asmuth DM, Kalish LA, Laycock ME, Murphy EL, Mohr BA, Lee TH, Gallarda J, Giachetti C, Dollard SC, van der Horst CM, Grant RM, Busch MP. PMID: 12662277.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    162. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol. 2003 04; 41(4):1586-93. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd RM, Reid C, Morgan GF, Winslow DL. PMID: 12682149.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    163. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol. 2003 04; 41(4):1594-9. Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, Day S, Lloyd RM, Reid C, Morgan GF, Winslow DL. PMID: 12682150.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    164. Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays. AIDS. 2003 Mar 07; 17(4):629-31. Hayden MS, Palacios EH, Grant RM. PMID: 12598787.
      View in: PubMed   Mentions: 5     Fields:    
    165. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS. 2003 Feb 14; 17(3):361-70. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ. PMID: 12556690.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    166. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS. 2002 Nov 22; 16(17):2342-4. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. PMID: 12441810.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    167. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol. 2002 Nov; 76(21):11104-12. Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, Deeks SG. PMID: 12368352.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    168. Drug Resistance Mutations in HIV-1. Top HIV Med. 2002 Nov-Dec; 10(5):21-25. D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. PMID: 12717052.
      View in: PubMed   Mentions: 15     Fields:    
    169. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. . 2002 Oct 01; 31(2):171-7. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W. PMID: 12394795.
      View in: PubMed   Mentions:
    170. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol. 2002 Aug; 76(15):7528-34. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P, Wiznia A, Grant RM, Bhardwaj N, Rosenberg MG, Nixon DF. PMID: 12097565.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    171. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002 Jul 10; 288(2):181-8. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. PMID: 12095382.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCells
    172. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS. 2002 May 24; 16(8):1103-11. Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, McCune JM. PMID: 12004268.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    173. Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med. 2002 Mar 18; 195(6):719-36. Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA. PMID: 11901198.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    174. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002 Jan 25; 16(2):201-7. Deeks SG, Barbour JD, Grant RM, Martin JN. PMID: 11807304.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    175. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 2002 Feb 01; 185(3):315-23. Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK. PMID: 11807713.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    176. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis. 2001 Dec 15; 184(12):1608-12. Roland ME, Martin JN, Grant RM, Hellmann NS, Bamberger JD, Katz MH, Chesney M, Franses K, Coates TJ, Kahn JO. PMID: 11740738.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    177. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS. 2001 Jul 06; 15(10):1251-9. Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG. PMID: 11426069.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    178. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med. 2001 Jun; 7(6):712-8. Stoddart CA, Liegler TJ, Mammano F, Linquist-Stepps VD, Hayden MS, Deeks SG, Grant RM, Clavel F, McCune JM. PMID: 11385509.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    179. Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses. 2001 Apr 10; 17(6):517-23. Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, Mammano F, Clavel F, Deeks SG, Grant RM, Goldsmith MA. PMID: 11350665.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    180. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001 Feb 15; 344(7):472-80. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. PMID: 11172188.
      View in: PubMed   Mentions: 156     Fields:    Translation:HumansCellsCTClinical Trials
    181. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001 Jan; 7(1):73-9. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, Herndier BG, Andersson J, McCune JM. PMID: 11135619.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCells
    182. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS. 2000 Dec 22; 14(18):2877-87. Parkin NT, Deeks SG, Wrin MT, Yap J, Grant RM, Lee KH, Heeren D, Hellmanna NS, Petropoulos CJ. PMID: 11153669.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    183. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis. 2001 Jan 01; 183(1):23-35. Celum CL, Buchbinder SP, Donnell D, Douglas JM, Mayer K, Koblin B, Marmor M, Bozeman S, Grant RM, Flores J, Sheppard HW. PMID: 11106536.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    184. Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol. 2000 Oct; 74(20):9594-600. Schramm B, Penn ML, Palacios EH, Grant RM, Kirchhoff F, Goldsmith MA. PMID: 11000231.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    185. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000 Mar; 181(3):946-53. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. PMID: 10720517.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    186. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis. 2000 Mar; 30(3):504-10. Huang SS, Barbour JD, Deeks SG, Huang JS, Grant RM, Ng VL, McCune JM. PMID: 10722435.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    187. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science. 2000 Jan 28; 287(5453):650-4. Blower SM, Gershengorn HB, Grant RM. PMID: 10649998.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCells
    188. Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis. 2000 Jan; 181(1):82-90. Greenblatt RM, Ameli N, Grant RM, Bacchetti P, Taylor RN. PMID: 10608754.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    189. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retroviruses. 1999 Dec 10; 15(18):1685-9. Locher CP, Grant RM, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO, Levy JA. PMID: 10606091.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    190. Evolution of viral quasispecies in interferon-treated patients with chronic hepatitis C virus infection. J Hepatol. 1999 Oct; 31(4):618-27. Hassoba HM, Bzowej N, Berenguer M, Kim M, Zhou S, Phung Y, Grant R, Pessoa MG, Wright TL. PMID: 10551384.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    191. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999 Jun 18; 13(9):1051-61. Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW. PMID: 10397535.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    192. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999 Jun; 179(6):1375-81. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. PMID: 10228057.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    193. Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol. 1999 Jun; 73(6):4829-39. Staprans SI, Dailey PJ, Rosenthal A, Horton C, Grant RM, Lerche N, Feinberg MB. PMID: 10233944.
      View in: PubMed   Mentions: 63     Fields:    Translation:AnimalsCells
    194. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999 Apr 16; 13(6):F35-43. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. PMID: 10397555.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    195. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir Ther. 1999; 4 Suppl 3:7-11. Deeks SG, Grant RM. PMID: 16021865.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    196. Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol. 1998 Dec; 72(12):9597-611. Kaur A, Grant RM, Means RE, McClure H, Feinberg M, Johnson RP. PMID: 9811693.
      View in: PubMed   Mentions: 63     Fields:    Translation:AnimalsCells
    197. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998 Jul 30; 339(5):307-11. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO. PMID: 9682043.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCells
    198. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS. 1998 Jul 09; 12(10):F97-102. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. PMID: 9677159.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    199. Parallel evolution of CCR5-null phenotypes in humans and in a natural host of simian immunodeficiency virus. Curr Biol. 1998 Jul 30-Aug 13; 8(16):943-6. Palacios E, Digilio L, McClure HM, Chen Z, Marx PA, Goldsmith MA, Grant RM. PMID: 9707408.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    200. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest. 1998 Jun 01; 101(11):2301-8. McCune JM, Loftus R, Schmidt DK, Carroll P, Webster D, Swor-Yim LB, Francis IR, Gross BH, Grant RM. PMID: 9616201.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    201. Not all is dead in HIV-1 graveyard. Lancet. 1998 Jan 31; 351(9099):308-9. Grant RM, Abrams DI. PMID: 9652607.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    202. Comparison of saliva and serum for human immunodeficiency virus type 1 antibody testing in Uganda using a rapid recombinant assay. Clin Diagn Lab Immunol. 1996 Nov; 3(6):640-4. Grant RM, Piwowar EM, Katongole-Mbidde E, Muzawalu W, Rugera S, Abima J, Stramer SL, Kataaha P, Jackson B. PMID: 8914752.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    203. Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis. 1996 Jan; 173(1):248-51. Chuck S, Grant RM, Katongole-Mbidde E, Conant M, Ganem D. PMID: 8537669.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    204. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995 Dec 01; 182(6):1727-37. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, Feinberg MB. PMID: 7500017.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    205. The high prevalence of genital herpes among patients with genital ulcer disease in Uganda. Sex Transm Dis. 1995 Nov-Dec; 22(6):351-4. Kamya MR, Nsubuga P, Grant RM, Hellman N. PMID: 8578407.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    206. Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis. 1995 May; 171(5):1338-43. Tsai CC, Follis KE, Sabo A, Grant R, Bischofberger N. PMID: 7538551.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    207. Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol. 1995 Mar; 2(2):233-5. Tugume SB, Piwowar EM, Lutalo T, Mugyenyi PN, Grant RM, Mangeni FW, Pattishall K, Katongole-Mbidde E. PMID: 7697535.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    208. beta-2 Microglobulin values among human immunodeficiency virus (HIV)-negative, HIV-positive asymptomatic, and HIV-positive symptomatic Ugandans. Clin Diagn Lab Immunol. 1995 Mar; 2(2):236-7. Piwowar EM, Tugume SB, Grant RM, Lutalo T, Pattishall K, Katongole-Mbidde E. PMID: 7697536.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    209. Cloning and characterization of the RNA polymerase alpha-subunit operon of Chlamydia trachomatis. J Bacteriol. 1993 Nov; 175(22):7150-9. Tan M, Klein R, Grant R, Ganem D, Engel J. PMID: 8226662.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    210. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 02; 320(5):293-6. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant RM, Crumpacker CS. PMID: 2536136.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimalsCells
    211. Infectivity of the human immunodeficiency virus: estimates from a prospective study of homosexual men. J Infect Dis. 1987 Jul; 156(1):189-93. Grant RM, Wiley JA, Winkelstein W. PMID: 3474298.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    212. Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study. JAMA. 1987 Jan 16; 257(3):326-30. Lang W, Anderson RE, Perkins H, Grant RM, Lyman D, Winkelstein W, Royce R, Levy JA. PMID: 3491910.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    213. Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA. 1987 Jan 16; 257(3):321-5. Winkelstein W, Lyman DM, Padian N, Grant R, Samuel M, Wiley JA, Anderson RE, Lang W, Riggs J, Levy JA. PMID: 3540327.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    Robert's Networks
    Concepts (558)
    Derived automatically from this person's publications.
    _
    Co-Authors (102)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _